Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001794664 | SCV002032533 | pathogenic | not provided | 2022-12-09 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002503278 | SCV002813225 | likely pathogenic | Polycystic kidney disease 3 with or without polycystic liver disease | 2021-09-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001794664 | SCV002945998 | pathogenic | not provided | 2022-09-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg164*) in the GANAB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GANAB are known to be pathogenic (PMID: 27259053). This variant is present in population databases (rs754785664, gnomAD 0.0009%). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 1327722). This variant has not been reported in the literature in individuals affected with GANAB-related conditions. |